| 词条 | CP-532,903 |
| 释义 |
| verifiedrevid = 417543408 | ImageFile=CP-532,903.svg | ImageSize=200px | IUPACName=(2S,3S,4R,5R)-3-amino-5-[6-(2,5-dichlorobenzylamino)purin-9-yl]-4-hydroxytetrahydrofuran-2-carboxylic acid methylamide | OtherNames=CP-532,903 |Section1={{Chembox Identifiers | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 8654410 | InChI = 1/C18H19Cl2N7O3/c1-22-17(29)14-11(21)13(28)18(30-14)27-7-26-12-15(24-6-25-16(12)27)23-5-8-4-9(19)2-3-10(8)20/h2-4,6-7,11,13-14,18,28H,5,21H2,1H3,(H,22,29)(H,23,24,25)/t11-,13+,14-,18+/m0/s1 | InChIKey = WFRYPIJMCFQCGT-MHMFGPJMBE | SMILES1 = Clc1cc(c(Cl)cc1)CNc4ncnc2c4ncn2[C@@H]3O[C@H](C(=O)NC)[C@@H](N)[C@H]3O | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C18H19Cl2N7O3/c1-22-17(29)14-11(21)13(28)18(30-14)27-7-26-12-15(24-6-25-16(12)27)23-5-8-4-9(19)2-3-10(8)20/h2-4,6-7,11,13-14,18,28H,5,21H2,1H3,(H,22,29)(H,23,24,25)/t11-,13+,14-,18+/m0/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = WFRYPIJMCFQCGT-MHMFGPJMSA-N | CASNo_Ref = {{cascite|correct|??}} | CASNo=457612-59-8 | PubChem = 10479002 | SMILES= Clc3ccc(Cl)cc3CNc(c1nc4)ncnc1n4C(C(O)C2N)OC2C(=O)NC |Section2={{Chembox Properties | Formula=C18H19Cl2N7O3 | MolarMass=452.294 | Appearance= | Density= | MeltingPt= | BoilingPt= | Solubility= |Section3={{Chembox Hazards | MainHazards= | FlashPt= | AutoignitionPt = }}CP-532,903 is a selective adenosine A3 subtype receptor agonist. It has antiinflammatory effects and has been shown to reduce superoxide generation in damaged tissues,[1] and protects against tissue damage following myocardial ischemia,[2] mediated via an interaction with ATP-sensitive potassium channels.[3] References1. ^van der Hoeven D, Wan TC, Auchampach JA. Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Molecular Pharmacology. 2008 Sep;74(3):685-96. {{PMID|18583455}} {{Adenosinergics}}{{nervous-system-drug-stub}}2. ^Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, Knight DR. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. American Journal of Physiology. Heart and Circulatory Physiology. 2003 Dec;285(6):H2780-7. {{PMID|12919933}} 3. ^Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, Auchampach JA. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. Journal of Pharmacology and Experimental Therapeutics. 2008 Jan;324(1):234-43. {{DOI|10.1124/jpet.107.127480}} {{PMID|17906066}} 7 : Nucleosides|Purines|Chloroarenes|Carboxamides|Pfizer|Pfizer products|Adenosine receptor agonists |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。